"Formoterol Fumarate" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An ADRENERGIC BETA-2 RECEPTOR AGONIST with a prolonged duration of action. It is used to manage ASTHMA and in the treatment of CHRONIC OBSTRUCTIVE PULMONARY DISEASE.
| Descriptor ID |
D000068759
|
| MeSH Number(s) |
D02.033.100.291.425 D02.092.063.291.425
|
| Concept/Terms |
Formoterol Fumarate- Formoterol Fumarate
- Formoterol Fumarate, ((R*,R*)-(+-))-isomer
- 3-Formylamino-4-hydroxy-alpha-(N-1-methyl-2-p-methoxyphenethylaminomethyl)benzyl alcohol.hemifumarate
|
Below are MeSH descriptors whose meaning is more general than "Formoterol Fumarate".
Below are MeSH descriptors whose meaning is more specific than "Formoterol Fumarate".
This graph shows the total number of publications written about "Formoterol Fumarate" by people in this website by year, and whether "Formoterol Fumarate" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2005 | 0 | 1 | 1 |
| 2007 | 0 | 1 | 1 |
| 2011 | 0 | 1 | 1 |
| 2014 | 0 | 2 | 2 |
| 2017 | 8 | 2 | 10 |
| 2018 | 11 | 0 | 11 |
| 2019 | 4 | 0 | 4 |
To return to the timeline, click here.
Below are the most recent publications written about "Formoterol Fumarate" by people in Profiles.
-
Two cases of chronic obstructive pulmonary disease evaluated by dynamic-ventilatory digital radiography for pulmonary function and assessment of treatment efficacy. Respir Investig. 2021 Nov; 59(6):871-875.
-
Inhaled budesonide for early treatment of COVID-19 - Authors' reply. Lancet Respir Med. 2021 07; 9(7):e61.
-
MMW Fortschr Med. 2021 04; 163(8):27-28.
-
Inhibitory effects of glycopyrronium, formoterol, and budesonide on coronavirus HCoV-229E replication and cytokine production by primary cultures of human nasal and tracheal epithelial cells. Respir Investig. 2020 May; 58(3):155-168.
-
Extrafine triple therapy in patients with symptomatic COPD and history of one moderate exacerbation. Eur Respir J. 2019 05; 53(5).
-
New opportunities of dual bronchodilation therapy for patients with chronic obstructive pulmonary disease. Ter Arkh. 2019 Mar 30; 91(3):76-85.
-
Extrafine triple therapy delays COPD clinically important deterioration vs ICS/LABA, LAMA, or LABA/LAMA. Int J Chron Obstruct Pulmon Dis. 2019; 14:531-546.
-
Efficacy of aclidinium/formoterol 400/12 µg, analyzed by airflow obstruction severity, age, sex, and exacerbation history: pooled analysis of ACLIFORM and AUGMENT. Int J Chron Obstruct Pulmon Dis. 2019; 14:479-491.
-
Beclomethasone dipropionate, formoterol fumarate and glycopyrronium bromide as a combination therapy for chronic obstructive pulmonary disease. Expert Rev Respir Med. 2019 01; 13(1):5-11.
-
Improved lung function and patient-reported outcomes with co-suspension delivery technology glycopyrrolate/formoterol fumarate metered dose inhaler in COPD: a randomized Phase III study conducted in Asia, Europe, and the USA. Int J Chron Obstruct Pulmon Dis. 2018; 13:2969-2984.